Sun Pharmaceutical Industries Limited has secured regulatory clearance from India’s premier stock exchanges to reclassify key members of its promoter group into the public category. The National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) issued no-objection letters dated August 06, 2026, approving the request submitted by the company on May 26, 2026. This move alters the shareholding structure classification for Krishna Vrundavandas Valia, Sudhir Vrundavandas Valia, and Raksha Sudhir Valia, shifting them from the ‘Promoter Group’ to the ‘Public’ category in accordance with Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The reclassification follows a series of prior intimations issued by Sun Pharmaceutical Industries Ltd on May 14, 2026, May 22, 2026, and May 26, 2026. The company notified stakeholders of its intent to seek this change, which is procedurally required when promoters wish to exit the promoter category or when their holding falls below specified thresholds, though the specific reason for this reclassification was not detailed in the exchange filings beyond the regulatory compliance aspect.

Reclassification Details

The no-objection letters from both exchanges confirm the approval for the following individuals:

The exchanges emphasized that Sun Pharmaceutical Industries Ltd must ensure compliance with subsequent relevant disclosures of material events related to this reclassification, as mandated by Regulation 31A of the SEBI Listing Regulations. Copies of the no-objection letters are available on the company’s website at www.sunpharma.com .

Regulatory Compliance

The intimation was issued under Regulation 30 and Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Anoop Anjanikumar Deshpande, Company Secretary and Compliance Officer of Sun Pharmaceutical Industries Ltd, signed the disclosure. The registered office of the company is located at SPARC, Tandalja, Vadodara, Gujarat.

This reclassification impacts how the shareholding pattern is reported in future quarterly disclosures. Shares held by the named individuals will now be aggregated under the public category rather than the promoter group, potentially affecting metrics related to promoter pledge limits and public float calculations, although the immediate financial impact remains neutral as it is a structural classification change rather than a transactional event.

Sun Pharmaceutical Industries Limited reported a consolidated net profit of ₹28,948 million for Q1FY27, rising year-on-year despite a 9.7% decline in US sales. The Mumbai-based pharma major posted revenue of ₹151,836 million, marking a 10.1% increase over the previous quarter. Strong performance in the domestic market, where sales grew 16%, and robust expansion in its innovative medicines portfolio offset headwinds in the US generics segment. The company also highlighted progress in its Organon acquisition, which is on track to close by early 2027.

Financial Performance

Consolidated revenue reached ₹151,836 million in Q1FY27, up from ₹138B in Q1FY26. Gross margin improved to 80.5%, driven by a better product mix with higher contributions from branded generics and innovative medicines. EBITDA stood at ₹44,177 million, a 2.7% increase year-on-year, with margins holding steady at 28.9%. CFO Jayashree Satagopan noted that adjusted EBITDA margins were higher than the prior year when excluding one-time benefits from Lenalidomide sales in Q1FY26.

Reported net profit after tax was ₹28,948 million, while adjusted net profit was ₹30,894 million. The effective tax rate (ETR) rose to 27.8% from 24.3% in Q1FY26, primarily due to the exhaustion of lower tax rates in India and varying rates across global jurisdictions. Exceptional items included a ₹1,617 million charge for Organon acquisition-related costs.

Regional Business Updates

The India business emerged as a key growth driver, with formulation sales reaching ₹54,749 million, a 16% year-on-year increase. This accounted for 36.1% of total consolidated sales. Sun Pharma reported a 5.4% volume growth, outperforming the industry average of 2%. The company secured the number 2 position for generic semaglutide injectables in India and holds an 8.5% market share in the domestic pharmaceutical sector.

In contrast, US sales declined 9.7% to USD 427 million. CEO North America Richard Ascroft attributed the drop to erosion in Lenalidomide sales and increased competition in certain generic products. However, the innovative medicines portfolio in the US grew, supported by launches like Leqselvi and Unloxcyt. Leqselvi surpassed 1,000 prescribers in June, while Unloxcyt gained traction in cancer centers due to its differentiated safety profile.

Emerging markets revenue was USD 311 million, up 4.2% year-on-year, while Rest of World (ROW) revenue remained flat at USD 218 million. Geopolitical issues and macroeconomic conditions impacted growth in some emerging economies.

Strategic Developments

Sun Pharma continues to advance its R&D pipeline, spending ₹8,264 million (5.4% of sales) in Q1FY27, with 30% allocated to innovative medicines. The company received approvals to manufacture generic semaglutide injection in Brazil and South Africa, with launches underway. Additionally, partner Philogen has resubmitted Nidlegly for marketing authorization in Europe.

The Organon acquisition process is nearing completion, with regulatory filings done in various markets and shareholder approval secured. An integration management office is preparing for day-one readiness, expecting closure in Q4FY27. The balance sheet remains strong with net cash of USD 3.4 billion at the consolidated level.